OMOlimpia Mora-Janiszewska

Olimpia Mora-Janiszewska

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Olimpia Mora-Janiszewska has a total of 6 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Reduced Methylation of IRF5 Gene as a Biomarker for Gestational Diabetes Mellitus

    by Mateusz Kunysz, Marek Cieśla, Olimpia Mora-Janiszewska, Dorota Darmochwał-Kolarz

    Reduced Methylation of IRF5 Gene as a Biomarker for Gestational Diabetes Mellitus - Article abstract #948320

  • Open Access

    A Review of Modulation of Gut Microbiota to Mitigate Gestational Diabetes: Implications for Maternal and Child Health

    by Olimpia Mora-Janiszewska, Kinga Bialic, Anna Faryniak, Dorota Darmochwał-Kolarz

    The increasing prevalence of gestational diabetes mellitus (GDM) is a pressing global public health concern. Despite extensive identification of GDM risk factors and the implementation of screening programs, there has been a notable lack of significant reduction in maternal, fetal, and neonatal complications. It is vital to recognize that the health trajectory of future generations begins before birth, during intrauterine life and even before conception. The development of 'diabetogenic' and 'obesogenic' changes in the DNA of offspring can be triggered not only by adverse intrauterine conditions, but also by changes in germ cell DNA at earlier stages. Accumulating evidence suggests that the increasing prevalence and persistent metabolic effects of GDM may be mediated by epigenetic modifications. The composition of the human gut microbiota is emerging as a key determinant of human metabolic processes. Consequently, dysbiosis of the gut microbiota via epigenetic mechanisms may contribute to metabolic complications in both the mother and the developing fetus. Given that diet plays a critical role in maintaining a healthy microbiota profile and that certain epigenetic alterations are reversible, it is pertinent to emphasize that not only the pregnant woman but also both partners attempting conception could influence the future health of the child. The aim of this article is to review the role of gut microbiota modulation in preventing and managing gestational diabetes mellitus and the health benefits for mother and child.


  • Open Access

    Epigenetic Links between Microbiota and Gestational Diabetes

    by Olimpia Mora-Janiszewska, Anna Faryniak-Zuzak, Dorota Darmochwał-Kolarz

    Gestational diabetes mellitus (GDM) is considered a significant and increasing worldwide problem. The growing body of evidence on this topic has allowed us to point out that a hostile intrauterine environment in mothers with GDM via epigenetic mechanisms induces “diabetogenic” and “obesogenic” changes in an offspring’s DNA. This sets a vicious intergenerational cycle of metabolic diseases in motion, gradually deteriorating the health of the human population. One of the most important participants of this process seems to be altered microbiota. There is a chance that the identification of specific epigenetic marks may provide a key for future diagnostic, prognostic and therapeutic solutions in the field of personalised medicine. Given the reversibility of most epigenetic changes, there is an opportunity to improve the long-term health of the human population. In this manuscript, we aim to summarise available data on epigenetic changes among women suffering from GDM and their progeny, in association with alterations in the microbiome.


  • Open Access

    Epigenetic Issues. The Link Between Microbiota and Gestational Diabetes.

    by Olimpia Mora-Janiszewska, Anna Faryniak-Zuzak, Dorota Darmochwał-Kolarz

    Gestational diabetes (GDM) is considered a significant and increasing problem worldwide. The growing body of evidence points out that a hostile intrauterine environment in mothers with GDM via epigenetic mechanisms induces "diabetogenic" and "obesogenic" changes in an offspring's DNA. This sets in motion a vicious intergenerational cycle of metabolic diseases gradually deteriorating the health of the human population. One of the most important players in this process seems to be altered microbiota/microbiome. There is a chance that the identification of specific epigenetic marks may provide a key for future diagnostic, prognostic and therapeutic solutions/measures in the field of person-alized medicine. Given the reversibility of most epigenetic changes, an opportunity arises to improve the long-term health of the human population/race. In this manuscript, we aim to summarize available data on epigenetic changes among women suffering from GDM and their progeny in association with changes in microbiome.


  • Open Access

    Epigenetic Modifications Associated with Exposure to Endocrine Disrupting Chemicals in Patients with Gestational Diabetes Mellitus

    by Mateusz Kunysz, Olimpia Mora-Janiszewska, Dorota Darmochwał-Kolarz

    Gestational diabetes mellitus (GDM) remains a significant clinical and public health issue due to its increasing prevalence and the possibility for numerous short- and long-term complications. The growing incidence of GDM seems to coincide with the widespread use of endocrine disrupting chemicals (EDCs). The extensive production and common use of these substances in everyday life has resulted in constant exposure to harmful substances from the environment. That may result in epigenetic changes, which may manifest themselves also after many years and be passed on to future generations. It is important to consider the possible link between environmental exposure to endocrine disrupting chemicals (EDCs) during pregnancy, epigenetic mechanisms and an increased risk for developing gestational diabetes mellitus (GDM). This manuscript attempts to summarize data on epigenetic changes in pregnant women suffering from gestational diabetes in association with EDCs. There is a chance that epigenetic marks may serve as a tool for diagnostic, prognostic, and therapeutic measures.